Reimbursement of a silver wound dressing on the U.K. Drug Tariff at a premium price.

Context: The U.K. National Health Service (NHS) includes a government-funded reimbursement scheme for medical devices within it's Drug Tariff.  The medical supplier had a silver dressing with a price significantly higher than the silver dressing already listed on the Drug Tariff.  The mission was to show that the dressing with the higher purchase price represented better value for money for the NHS.
Actions: Health economic data was designed and collected alongside the clinical trial of the dressing.  The trial data was analysed to show where and how the supplier's silver dressing was cost-effective compared with the silver dressing already listed on the Drug Tariff.
Outcome: The silver dressing was listed on the Drug Tariff at a premium price, resulting in increased sales volume with a healthy profit margin.

Disclaimer | Copyright Statement